Diplomat receives limited-distribution contract for BETHKIS® (tobramycin inhalation solution)
FLINT, Mich. — Nov. 22 2013 — Diplomat, the nation’s largest independent specialty pharmacy, has been chosen as a distributor for BETHKIS® (tobramycin inhalation solution.) BETHKIS® is a concentrated dosing solution for the treatment of chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients. BETHKIS® was approved by the FDA in October 2013 with a product launch this fall by Cornerstone Therapeutics. Diplomat has access to dispense BETHKIS® immediately.
According to the Cystic Fibrosis Foundation, more than 30,000 children and adults are living with cystic fibrosis, an inherited chronic disease, with 1,000 new cases diagnosed each year. Cystic fibrosis is caused by a defect in the cystic fibrosis transmembrane conductance regulator gene. This defect causes the body to produce unusually thick, sticky mucus that alters normal processes in the lungs and leads to chronic bronchial infections. Inhaled tobramycin is recommended to improve lung function and reduce exacerbations for cystic fibrosis patients aged 6 or older experiencing moderate to severe lung disease and showing P. aeruginosa in cultures of the airways.
Per manufacturer’s instructions, BETHKIS® is administered as a concentrated solution delivering 300mg of nebulized tobramycin in only 4mL, twice daily in alternating 28-day cycles. BETHKIS® is not recommended for patients with a known hypersensitivity to any aminoglycoside.
BETHKIS® is marketed by Cornerstone Therapeutics Inc. based in Cary, N.C. Full prescribing information for BETHKIS® is available on the Cornerstone Therapeutics website.
About Cornerstone Therapeutics, Inc.
Founded in 2000, Cornerstone Therapeutics is a specialty pharmaceutical company focused on commercializing products for the hospital, niche respiratory and related markets.
Contact: Barbara Fornasiero, EAFocus Communications; 248.651.7536, Cell: 586.817.8414, firstname.lastname@example.org. Abigail Bearman, Diplomat; 810.768.9563; email@example.com. Gary Rice, R.Ph., Diplomat; 810.768.9863, firstname.lastname@example.org.
@BusLeadersforMIRT @BusLeadersforMI: Hear from Mike Miller, Director of @Google Tech Services & Phil Hagerman, CEO of @DiplomatRx at 11/9 #MICEOSummit! htt…1 hour ago
@SpecialtyPTimesRT @SpecialtyPTimes: Happy #WorldPharmacistDay to our wonderful followers who make a difference in patient lives every day! How are you cel…4 hours ago
@DiplomatRx@BuntyLUFC We appreciate you reaching out. Would you mind direct messaging us so we can help?5 days ago
@DiplomatRxOur Navigating Patient Engagement webinar is available on demand. Sign up at https://t.co/LN1qWkrCZp to watch the r… https://t.co/RaQGhk3xF75 days ago
@SpecialtyPharmRT @SpecialtyPharm: Specialty Pharmacies Earn High Marks in First NASP Patient Satisfaction @Rx_Specialty Survey #NASP2017 https://t.co/B0k…5 days ago